Malignant melanoma is one of the most common tumours and has the highest mortality rate
of all types of skin cancers worldwide. Traditional and novel therapeutic approaches …

Melanoma is the most lethal form of skin cancer and its incidence is rapidly rising.
Breakthroughs in the understanding of the basic biology of melanoma in the past decade …

Melanoma is a malignant proliferative disease originated in melanocytes, characterized by
high metastatic activity and by the activation of oncogenes, such as B-RAF (40–60% of …

Melanoma and its associated alterations in cellular pathways have been growing areas of
interest in research, especially as specific biological pathways are being elucidated. Some …

The expression and subcellular localization of immune checkpoint protein PD-L1 have been
implicated to play an important role in cancer immunotherapy. In a recent paper published in …

PD-1 blockade therapy has revolutionized cancer treatments. However, a substantial
population of patients is unresponsive. To rescue unresponsive patients, the mechanism of …

Immunotherapy based on programmed cell death protein-1 (PD-1) is a promising approach
in oncology. However, a significant fraction of patients remain unresponsive. Therefore, it is …

PARP-1 inhibition has recently been employed in both mono-and combination therapies in
various malignancies including melanoma with both promising and contradicting results …

Although immunotherapy by PD-1 blockade has dramatically improved the survival rate of
cancer patients, further improvement in efficacy is required to reduce the fraction of less …

The Warburg effect in tumour cells is associated with the upregulation of glycolysis to
generate ATP, even under normoxic conditions and the presence of fully functioning …